JP2020510619A - ミカファンギン組成物 - Google Patents

ミカファンギン組成物 Download PDF

Info

Publication number
JP2020510619A
JP2020510619A JP2019529625A JP2019529625A JP2020510619A JP 2020510619 A JP2020510619 A JP 2020510619A JP 2019529625 A JP2019529625 A JP 2019529625A JP 2019529625 A JP2019529625 A JP 2019529625A JP 2020510619 A JP2020510619 A JP 2020510619A
Authority
JP
Japan
Prior art keywords
aqueous pharmaceutical
pharmaceutical composition
composition
micafungin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019529625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510619A5 (enExample
Inventor
シドニー・ジェイ・コープ
クリスティーン・エル・レベック
マーク・ジェイ・ドーティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of JP2020510619A publication Critical patent/JP2020510619A/ja
Publication of JP2020510619A5 publication Critical patent/JP2020510619A5/ja
Priority to JP2023189549A priority Critical patent/JP2024012211A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019529625A 2016-12-16 2017-12-15 ミカファンギン組成物 Withdrawn JP2020510619A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023189549A JP2024012211A (ja) 2016-12-16 2023-11-06 ミカファンギン組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435695P 2016-12-16 2016-12-16
US62/435,695 2016-12-16
PCT/US2017/066652 WO2018112330A1 (en) 2016-12-16 2017-12-15 Micafungin compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023189549A Division JP2024012211A (ja) 2016-12-16 2023-11-06 ミカファンギン組成物

Publications (2)

Publication Number Publication Date
JP2020510619A true JP2020510619A (ja) 2020-04-09
JP2020510619A5 JP2020510619A5 (enExample) 2021-01-28

Family

ID=60972375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019529625A Withdrawn JP2020510619A (ja) 2016-12-16 2017-12-15 ミカファンギン組成物
JP2023189549A Pending JP2024012211A (ja) 2016-12-16 2023-11-06 ミカファンギン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023189549A Pending JP2024012211A (ja) 2016-12-16 2023-11-06 ミカファンギン組成物

Country Status (11)

Country Link
US (2) US12403173B2 (enExample)
EP (1) EP3554474B1 (enExample)
JP (2) JP2020510619A (enExample)
AU (1) AU2017376960B2 (enExample)
DK (1) DK3554474T3 (enExample)
ES (1) ES2972008T3 (enExample)
FI (1) FI3554474T3 (enExample)
HU (1) HUE066069T2 (enExample)
PL (1) PL3554474T3 (enExample)
PT (1) PT3554474T (enExample)
WO (1) WO2018112330A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111044636A (zh) * 2019-12-30 2020-04-21 卓和药业集团有限公司 米卡芬净含量的分析方法
US20220040092A1 (en) * 2020-06-27 2022-02-10 RK Pharma Solutions LLC Ready to use injectable formulations of Micafungin Sodium
CN112710753A (zh) * 2020-12-18 2021-04-27 卓和药业集团有限公司 米卡芬净有关物质的分析方法
WO2024233925A1 (en) * 2023-05-11 2024-11-14 Hikma Pharmaceuticals Usa Inc. Stable micafungin compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533056A (ja) * 2002-06-13 2005-11-04 バイクロン ファーマシューティカルズ， インコーポレイテッド 非経口抗真菌生成物
CN102512379A (zh) * 2011-12-16 2012-06-27 深圳市健元医药科技有限公司 一种新型棘白菌素类抗真菌药物组合物及其制备方法
JP2014504615A (ja) * 2011-01-31 2014-02-24 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッド エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849843A (en) 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
US5998019A (en) 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
MX9702531A (es) 1994-10-07 1997-06-28 Fujisawa Pharmaceutical Co Compuesto nuevo.
TWI233805B (en) 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
CN103360486A (zh) 2004-08-18 2013-10-23 诺瓦生命科学有限公司 包含含有精氨酸和/或赖氨酸的基序的抗微生物肽
WO2008137128A2 (en) 2007-05-03 2008-11-13 Northeastern University Methods of treating fungal infections
AU2013254940A1 (en) 2008-04-21 2014-01-16 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
MX2010012451A (es) 2008-05-15 2010-12-07 Baxter Int Formulaciones farmaceuticas estables.
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US20110071072A1 (en) * 2009-08-28 2011-03-24 Georgetown University, A Congressionally Chartered Institution Of Higher Education Antifungal Bone Cements
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
DK3240529T3 (da) * 2014-12-31 2022-02-28 Galenicum Health S L U Stabile farmaceutiske sammensætninger omfattende micafungin
CN108290845B (zh) * 2015-10-07 2021-08-03 大日本住友制药株式会社 嘧啶化合物
IN2015MU03858A (enExample) * 2015-10-10 2015-10-23 Gufic Biosciences Ltd

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533056A (ja) * 2002-06-13 2005-11-04 バイクロン ファーマシューティカルズ， インコーポレイテッド 非経口抗真菌生成物
JP2014504615A (ja) * 2011-01-31 2014-02-24 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッド エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物
CN102512379A (zh) * 2011-12-16 2012-06-27 深圳市健元医药科技有限公司 一种新型棘白菌素类抗真菌药物组合物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
北河 修治 編, ベーシック薬学教科書シリーズ20 薬剤学（第２版）, JPN6022040810, 2013, pages 95 - 100, ISSN: 0005098195 *

Also Published As

Publication number Publication date
US20250345386A1 (en) 2025-11-13
US20180169180A1 (en) 2018-06-21
HUE066069T2 (hu) 2024-07-28
EP3554474B1 (en) 2023-12-06
FI3554474T3 (fi) 2024-02-21
AU2017376960B2 (en) 2023-12-14
DK3554474T3 (da) 2024-02-19
PL3554474T3 (pl) 2024-04-15
WO2018112330A1 (en) 2018-06-21
AU2017376960A1 (en) 2019-05-23
PT3554474T (pt) 2024-02-12
JP2024012211A (ja) 2024-01-25
ES2972008T3 (es) 2024-06-10
EP3554474A1 (en) 2019-10-23
US12403173B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
US20250345386A1 (en) Micafungin compositions
JP5778384B2 (ja) エスモロール処方物
US8034830B2 (en) Argatroban formulation
AU2013261012B2 (en) Ready to be infused gemcitabine solution
CA2410446C (en) Esmolol formulation
US10933019B2 (en) Liquid formulations of daptomycin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230704

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240115